Primary Job Title Founder, Chairman of the Board, CEO & CSO Primary Organization 
CARsgen Therapeutics
Location Xuhui, Shanghai, China Regions Asia-Pacific (APAC) Gender Male
Zonghai Li, M.D., Ph.D., is the Chairman, Chief Executive Officer, Chief Scientific Officer and Founder of CARsgen Therapeutics. He was a professor and now an adjunct professor in Shanghai Cancer Institute, Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine.
Zonghai Li is dedicated himself to develop innovative
treatment for the patients with cancer. One of his early career achievements is the identification of GE11, a peptide ligand of EGFR which has become the most widely used unnatural peptide in antitumor study now. He is the inventor of many new technologies such as Hpd3cell, a new phage display technology; FR806, a new safety switch for T cell therapy; Run-CAR technology to increase the antitumor activities of chimeric antigen receptor (CAR) T cells. He has a leading role in the research on CAR T cell therapy against solid tumors by publishing the first paper of CAR T cell therapy against GPC3, Claudin18.2 and EGFR/EGFRvIII worldwide.
Zonghai Li earned a M.D. and M.S. from Xiangya Medical School of Central South University and a Ph.D. from Shanghai Medical College of Fudan University.
